(3-dimyristyloxypropyl)(dimethyl)(hydroxyethyl)ammonium has been researched along with Sarcoma in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (100.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Akporiaye, ET; Burch, P; Edmonson, J; Forscher, C; Galanis, E; Gonzalez, R; Hersh, EM; Lewis, BD; O'Driscoll, M; Rinehart, JJ; Rubin, J; Selk, L; Sobol, RE; Sondak, VK; Spier, C; Stopeck, AT; Unger, EC | 1 |
1 trial(s) available for (3-dimyristyloxypropyl)(dimethyl)(hydroxyethyl)ammonium and Sarcoma
Article | Year |
---|---|
Immunotherapy of advanced malignancy by direct gene transfer of an interleukin-2 DNA/DMRIE/DOPE lipid complex: phase I/II experience.
Topics: Adult; Aged; Carcinoma, Renal Cell; CD8 Antigens; Dose-Response Relationship, Drug; Female; Gene Transfer Techniques; Genetic Therapy; Humans; Immunohistochemistry; Interleukin-2; Kidney Neoplasms; Lipids; Male; Melanoma; Middle Aged; Plasmids; Polymerase Chain Reaction; Quaternary Ammonium Compounds; Sarcoma; Skin Neoplasms | 1999 |